Your session is about to expire
← Back to Search
Lepodisiran Sodium for Elevated Lipoprotein
Study Summary
This trial aims to test whether lepodisiran can reduce the risk of heart disease in people with high lipoprotein(a) levels who already have heart disease or are at risk of a heart attack
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are individuals currently eligible to apply for participation in this ongoing medical study?
"According to clinicaltrials.gov, the current trial is not actively enrolling participants. The information was first posted on March 1st, 2024 and last updated on the same day. Despite this trial being inactive for recruitment at present, there are numerous other studies seeking volunteers; specifically, 556 trials are presently recruiting participants."
In how many medical facilities is this examination being conducted?
"IBPClin - Instituto Brasil de Pesquisa Clínica in Rio de Janeiro, Nordjylland, Sanos Clinic - Nordjylland in Gandrup, Rio Grande Do Sul and Hospital Moinhos de Vento in Porto Alegre, Pennsylvania are among the 12 additional sites where patients can enroll for this trial."
Has the Food and Drug Administration officially sanctioned Lepodisiran Sodium for use?
"According to our analysis at Power, Lepodisiran Sodium has been rated a 3 for safety in this Phase 3 trial. This rating is indicative of existing efficacy data and substantial evidence supporting its safety profile."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger